A two-center study of MRI and clinical parameter-based nomogram for predicting the efficacy of D-TACE in hepatocellular carcinoma

WANG Jieyu; XI Zihan; TIAN Yuchi; YANG Yongbo; QIU Huafeng; ZENG Hui; LIANG Xiaoyun; JIANG Haitao

doi:10.16766/j.cnki.issn.1674-4152.003743

Volume 22 Issue 11

Nov. 2024

Turn off MathJax

Article Contents

Article Navigation > Chinese Journal of General Practice > 2024 > 22(11): 1827-1832

WANG Jieyu, XI Zihan, TIAN Yuchi, YANG Yongbo, QIU Huafeng, ZENG Hui, LIANG Xiaoyun, JIANG Haitao. A two-center study of MRI and clinical parameter-based nomogram for predicting the efficacy of D-TACE in hepatocellular carcinoma[J]. Chinese Journal of General Practice, 2024, 22(11): 1827-1832. doi: 10.16766/j.cnki.issn.1674-4152.003743

Citation:

WANG Jieyu, XI Zihan, TIAN Yuchi, YANG Yongbo, QIU Huafeng, ZENG Hui, LIANG Xiaoyun, JIANG Haitao. A two-center study of MRI and clinical parameter-based nomogram for predicting the efficacy of D-TACE in hepatocellular carcinoma[J]. Chinese Journal of General Practice, 2024, 22(11): 1827-1832. doi: 10.16766/j.cnki.issn.1674-4152.003743

Citation:

WANG Jieyu, XI Zihan, TIAN Yuchi, YANG Yongbo, QIU Huafeng, ZENG Hui, LIANG Xiaoyun, JIANG Haitao. A two-center study of MRI and clinical parameter-based nomogram for predicting the efficacy of D-TACE in hepatocellular carcinoma[J]. Chinese Journal of General Practice, 2024, 22(11): 1827-1832. doi: 10.16766/j.cnki.issn.1674-4152.003743

PDF( 585 KB)

A two-center study of MRI and clinical parameter-based nomogram for predicting the efficacy of D-TACE in hepatocellular carcinoma

doi: 10.16766/j.cnki.issn.1674-4152.003743

1.
Postgraduate Training Base Alliance of Wenzhou Medical University, Wenzhou, Zhejiang 325000, China

Funds:

2023KY598

2021KY567

Received Date: 2024-07-18
Available Online: 2024-12-31

Abstract

Abstract

Objective To investigate the effects of preoperative imaging features on baseline contrast-enhanced MRI, as well as clinically relevant factors on the efficacy of drug-eluting bead transarterial chemoembolization (D-TACE). Methods A retrospective analysis of patients from two centers who received D-TACE as initial therapy was conducted, with the objective of assessing tumour response after D-TACE according to the modified response tumour evaluation criteria in solid tumours. The objective was to identify the independent factors related to the short-term outcomes of D-TACE. This was achieved by applying univariate and multivariate logistic regression methods, and a nomogram was established. The area under the curve (AUC) was calculated by plotting the receiver operating characteristic (ROC). The factors associated with PFS were determined by means of a multivariate Cox regression analysis. Results The study cohort comprised 145 patients. The results of the multivariate logistic regression analysis indicated that GGT, tumour-to-liver volume ratio, drug-loaded status, and portal vein tumour thrombus was significantly associated with short-term outcomes following D-TACE. Following internal validation by the bootstrap method, the area under the curve (AUC) value of the constructed nomogram was 0.796 (95% CI: 0.719-0.864). The calibration curves demonstrate a high degree of concordance between the predicted and actual values of the model, which indicates an excellent predictive performance. The decision curve analysis indicates that the nomogram performs well in clinical applications. Multivariate Cox regression analysis revealed that gender and postoperative short-term outcomes were significant factors affecting PFS. Conclusion The nomogram, constructed from contrast-enhanced MRI imaging features and clinically relevant parameters, has been demonstrated to be an effective predictor of first D-TACE short-term outcomes. It is anticipated that this nomogram will facilitate the identification of patients who are likely to benefit from D-TACE. Female patients and those with postoperative short-term outcomes of CR, PR, and SD had longer PFS.
- Hepatocellular carcinoma,
- Drug-eluting bead transarterial chemoembolization,
- Magnetic resonance imaging,
- Progression-free survival,
- Nomogram

FullText(HTML)

References(26)

References

[1]	CHIDAMBARANATHAN-REGHUPATY S, FISHER P B, SARKAR D. Hepatocellular carcinoma (HCC): epidemiology, etiology and molecular classification[J]. Adv Cancer Res, 2021, 149: 1-61.
[2]	郑荣寿, 陈茹, 韩冰峰, 等. 2022年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2024, 46(3): 221-231. doi: 10.3760/cma.j.cn112152-20240119-00035 ZHENG R S, CHEN R, HAN B F, et al. Cancer incidence and mortality in China, 2022[J]. Chinese Journal of Oncology, 2024, 46(3): 221-231. doi: 10.3760/cma.j.cn112152-20240119-00035
[3]	ZHOU J, SUN H C, WANG Z, et al. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (2019 edition)[J]. Liver Cancer, 2020, 9(6): 682-720. doi: 10.1159/000509424
[4]	NOURI Y M, KIM J H, YOON H K, et al. Update on transarterial chemoembolization with drug-eluting microspheres for hepatocellular carcinoma[J]. Korean J Radiol, 2019, 20(1): 34-49. doi: 10.3348/kjr.2018.0088
[5]	CHANG Y, JEONG S W, YOUNG JANG J, et al. Recent updates of transarterial chemoembolilzation in hepatocellular carcinoma[J]. Int J Mol Sci, 2020, 21(21) : 8165. DOI: 10.3390/ijms21218165.
[6]	SHI Q, LIU J C, LI T Q, et al. Comparison of DEB-TACE and cTACE for the initial treatment of unresectable hepatocellular carcinoma beyond up-to-seven criteria: a single-center propensity score matching analysis[J]. Clin Res Hepatol Gastroenterol, 2022, 46(5): 101893. DOI: 10.1016/j.clinre.2022.101893.
[7]	于翔, 谢坪, 李金泽, 等. 预测DEB-TACE治疗肝细胞肝癌术后生存率的放射组学列线图[J]. 介入放射学杂志, 2022, 31(1): 39-44. YU X, XIE P, LI J Z, et al. Application of CT radiomics nomogram model in predicting the survival time of patients with hepatocellular carcinoma after receiving drug-eluting beads transarterial chemoembolization[J]. Journal of Interventional Radiology, 2022, 31(1): 39-44.
[8]	TIPALDI M A, RONCONI E, LUCERTINI E, et al. Hepatocellular carcinoma drug-eluting bead transarterial chemoembolization (DEB-TACE): outcome analysis using a model based on pre-treatment ct texture features[J]. Diagnostics (Basel), 2021, 11(6): 956. DOI: 10.3390/diagnostics11060956.
[9]	ZHANG X Y, HE Z J, ZHANG Y C, et al. Prediction of initial objective response to drug-eluting beads transcatheter arterial chemoembolization for hepatocellular carcinoma using ct radiomics-based machine learning model[J]. Front Pharmacol, 2024, 15: 1315732. DOI: 10.3389/fphar.2024.1315732.
[10]	LENCIONI R, LLOVET J M. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma[J]. Semin Liver Dis, 2010, 30(1): 52-60. doi: 10.1055/s-0030-1247132
[11]	SUN P, LI Y L, CHANG L J, et al. Prognostic and clinicopathological significance of gamma-glutamyltransferase in patients with hepatocellular carcinoma: a prisma-compliant meta-analysis[J]. Medicine (Baltimore), 2019, 98(19): e15603. DOI: 10.1097/MD.0000000000015603.
[12]	YAN H W, WANG X H, ZHOU D D, et al. Dynamic nomogram for predicting macrovascular invasion of patients with unresectable hepatocellular carcinoma after transarterial chemoembolization[J]. J Cancer, 2022, 13(6): 1914-1922. doi: 10.7150/jca.69548
[13]	KE Q, XIANG F, XIAO C H, et al. Exploring the clinical value of preoperative serum gamma-glutamyl transferase levels in the management of patients with hepatocellular carcinoma receiving postoperative adjuvant transarterial chemoembolization[J]. BMC Cancer, 2021, 21(1): 1117. DOI: 10.1186/s12885-021-08843-z.
[14]	SUN Y, XIONG Y Q, WANG Q, et al. Development and validation of a nomogram to predict the recurrence of hepatocellular carcinoma patients with dynamic changes in afp undergoing locoregional treatments[J]. Front Oncol, 2023, 13: 1206345. DOI: 10.3389/fonc.2023.1206345.
[15]	SHAO G L, ZOU Y H, LUCATELLI P, et al. Chinese expert consensus on technical recommendations for the standard operation of drug-eluting beads for transvascular embolization[J]. Ann Transl Med, 2021, 9(8): 714. DOI: 10.21037/atm-21-1678.
[16]	ZHAO Y, HAROUN R R, SAHU S, et al. Three-dimensional quantitative tumor response and survival analysis of hepatocellular carcinoma patients who failed initial transarterial chemoembolization: repeat or switch treatment?[J]. Cancers (Basel), 2022, 14(15): 3615. DOI: 10.3390/cancers14153615.
[17]	HAJKOVA M, ANDRASINA T, OVESNA P, et al. Volumetric analysis of hepatocellular carcinoma after transarterial chemoembolization and its impact on overall survival[J]. In Vivo, 2022, 36(5): 2332-2341. doi: 10.21873/invivo.12964
[18]	BORDE T, NEZAMI N, LAAGE GAUPP F, et al. Optimization of the bclc staging system for locoregional therapy for hepatocellular carcinoma by using quantitative tumor burden imaging biomarkers at MRI[J]. Radiology, 2022, 304(1): 228-237. doi: 10.1148/radiol.212426
[19]	KHAN A R, WEI X Y, XU X. Portal vein tumor thrombosis and hepatocellular carcinoma-the changing tides[J]. J Hepatocell Carcinoma, 2021, 8: 1089-1115. doi: 10.2147/JHC.S318070
[20]	胡舟朝, 王和平, 严金岗, 等. 肝动脉化疗栓塞联合射频消融治疗巴塞罗那分期中晚期肝癌的预后影响因素分析[J]. 中华全科医学, 2022, 20(9): 1495-1497, 1525. doi: 10.16766/j.cnki.issn.1674-4152.002632 HU Z C, WANG H P, YAN J G, et al. Prognostic factors of transarterial chemoembolization combined with radiofrequency ablation for advanced Barcelona clinic liver cancer[J]. Chinese Journal of General Practice, 2022, 20(9): 1495-1497, 1525. doi: 10.16766/j.cnki.issn.1674-4152.002632
[21]	JI K, ZHU H L, WU W, et al. Tumor response and nomogram-based prognostic stratification for hepatocellular carcinoma after drug-eluting beads transarterial chemoembolization[J]. J Hepatocell Carcinoma, 2022, 9: 537-551. doi: 10.2147/JHC.S360421
[22]	CHENG S H, YU X, LIU S Y, et al. Development of a prognostic nomogram in hepatocellular carcinoma with portal vein tumor thrombus following trans-arterial chemoembolization with drug-eluting beads[J]. Cancer Manag Res, 2021, 13: 9367-9377. doi: 10.2147/CMAR.S341672
[23]	NEVOLA R, TORTORELLA G, ROSATO V, et al. Gender differences in the pathogenesis and risk factors of hepatocellular carcinoma[J]. Biology (Basel), 2023, 12(7): 984. DOI: 10.3390/biology12070984.
[24]	KONG J J, WANG T, SHEN S, et al. A nomogram predicting the prognosis of young adult patients diagnosed with hepatocellular carcinoma: a population-based analysis[J]. PLoS One, 2019, 14(7): e0219654. DOI: 10.1371/journal.pone.0219654.
[25]	江振辉, 胡晓川, 吴文明, 等. 肝癌术后预后列线图的建立和验证[J]. 肝胆胰外科杂志, 2023, 35(11): 649-659. JIANG Z H, HU X C, WU W M, et al. Establishment and validation of a nomogram to predict prognosis of hepatocellular carcinoma after surgery[J]. Journal of Hepatopancreatobiliary Surgery, 2023, 35(11): 649-659.
[26]	PARK C, CHU H H, KIM J H, et al. Clinical significance of the initial and best responses after chemoembolization in the treatment of intermediate-stage hepatocellular carcinoma with preserved liver function[J]. J Vasc Interv Radiol, 2020, 31(12): 1998-2006. e1. DOI: 10.1016/j.jvir.2020.04.017.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(2) / Tables(7)

Get Citation

PDF

XML

Article Metrics

Article views (106) PDF downloads(2)

A two-center study of MRI and clinical parameter-based nomogram for predicting the efficacy of D-TACE in hepatocellular carcinoma

doi: 10.16766/j.cnki.issn.1674-4152.003743

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

A two-center study of MRI and clinical parameter-based nomogram for predicting the efficacy of D-TACE in hepatocellular carcinoma

doi: 10.16766/j.cnki.issn.1674-4152.003743

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Export File

Citation

Format

Content